Skip to main content
Carmot Therapeutics Inc. (CRMO)
Carmot Therapeutics was planning to go public, but the IPO was withdrawn on Dec 11, 2023.
Stock Price: Pending
IPO price not available yet

Carmot Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
 20222021
Selling, General & Admin
6.284.5
Research & Development
37.1520.09
Operating Expenses
43.4324.59
Operating Income
-43.43-24.59
Interest Expense / Income
-1.43-1.74
Other Expense / Income
-1.5-49.99
Pretax Income
-40.527.13
Income Tax
-1.661.76
Net Income
-38.8325.37
Free Cash Flow
-39.45-24.66
Effective Tax Rate
-6.48%
EBITDA
-41.2925.9
Depreciation & Amortization
0.640.51
EBIT
-41.9325.4
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).